HCV-discovery to elimination, 'myth or reality'

作     者：Wasim Jafri Basit Siddiqui Safia Awan 

作者机构：Aga Khan University Department of MedicineSection of GastroenterologyKarachi 75500Pakistan 

出 版 物：《Hepatoma Research》 (肝癌研究（英文版）)

年 卷 期：2018年第4卷第9期

页      面：37-44页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Hepatitis C virus elimination directly acting antiviral agents Pakistan 

摘      要：Hepatitis C virus (HCV) was discovered in 1989, before that it was commonly known as transfusion associated non A non B hepatitis. It rapidly assumed the role of leading cause of cirrhosis and liver cancer and a leading indication for liver transplant globally. For over two decades the treatment was suboptimal with the use of pegylated interferon and ribavirin combination across all genotypes. The vaccine development also failed for over two decades. However a major breakthrough happened in December 2013 when the Food and Drug Administration (FDA) approved the first pan genotypic oral directly acting drug Sofosbuvir. Since then many new directly acing drugs have been approved through fast track by the FDA. Today we have directly acting antiviral agents for all HCV patients providing cure rates of over 90%. Looking into this success the World Health Organization has set targets for 2030 for HCV elimination. There are several countries which have formed strategies to achieve this goal and others are still thinking to develop their own strategies. The availability of generics have reduced the prices substantially, however the problem is so gigantic that unless proper operational strategies for elimination are developed by the developing world especially by China and Pakistan, the two counties having the largest existing pool of HCV patients, the goals of elimination may not come true.